Data retention and archiving in non-interventional studies (NIS) are foundational practices that support the integrity of the scientific process, comply with regulatory requirements, facilitate future research, serve educational purposes, and ensure ethical management of study data. These practices are essential for advancing knowledge, fostering innovation, and ultimately improving health outcomes.
In many jurisdictions, regulatory bodies mandate the retention of research data for a specified period (see below).
Argentina = 2 years
Austria = 15 years
Brazil = 5 years
Germany = 10 years
Japan = 5 years
Netherlands = 15 years
South Korea = 3 years
Turkey = 5 years
Pain Point #1 = Most countries don’t define how long you should retain NIS documents. In these cases, we recommend you defer (refer) to IPSE GPP data retention guidance = At least 5 years after final report or first publication of study results.
Pain Point #2 = Trying to force your non-interventional (observational) study documents into a filing system designed specifically for clinical trials. There is a (reasonably) simple solution for this. Use the real world study document index that was developed from the TMF Reference Model by NIS experts who were keen to mitigate this pain.
CDISC Real World Study Document Index: https://www.cdisc.org/sites/default/files/2023-09/Real_World_Studies_Document_Index_v1_2020_07_29.xlsx
CDISC TMF Reference Model: https://www.cdisc.org/tmf
In conclusion, through adherence to established guidelines and the utilization of resources like the CDISC Real World Study Document Index, researchers can navigate the complexities of data retention, thereby contributing to the broader goals of enhancing knowledge, spurring innovation, and improving global health outcomes.
Share this story...
Real World Evidence (RWE) 201 – Beyond Clinical Trials: Health Canada’s Commitment to Real World Evidence
RWE 201 - Beyond Clinical Trials: Health Canada's Commitment to Real World Evidence Health Canada is dedicated to enhancing drug accessibility, affordability, and correct usage within the country. To [...]
Real World Evidence (RWE) 201 – A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA
RWE 201 - A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA Non-interventional studies are different from randomized controlled trials (RCTs). Instead of actively intervening in a [...]
Real World Evidence (RWE) 201 – FDA’s Advancing RWE Program
RWE 201 - FDA's Advancing RWE Program Real-world evidence is transforming the regulatory landscape, enabling the FDA to make informed decisions based on robust data from real-world settings. [...]
Real World Evidence (RWE) 201 – FDA’s RWE Considerations Draft Guidance
RWE 201 - FDA's RWE Considerations Draft Guidance The 21st Century Cures Act, signed into law in 2016, mandated the FDA to establish a framework for the evaluation of [...]
Real World Evidence 201 – FDAs RWE Framework
RWE 201 - FDAs RWE Framework Real World Evidence (RWE) 201 – FDAs RWE Framework RWE 201: https://rwr-regs.com/rwe-201/ The FDA's Real-World Evidence (RWE) Program framework, established under the [...]
Real World Evidence 201 – The 21st Century Cures Act
RWE 201 - The 21st Century Cures Act The 21st Century Cures Act (CURES 1.0), signed into law in the U.S. in December 2016, aimed to accelerate [...]







